TATA HEALTH (01255) announced that on September 4, 2025, the company received a letter from the Hong Kong Stock Exchange setting out additional guidance for the resumption of trading of the shares on the Stock Exchange (the "Additional Resumption Guidance", together with the Initial Resumption Guidance, collectively the "Resumption Guidance"):
Re-compliance with Rule 3.10(2) of the Listing Rules.
Additionally, the company's shares continue to be suspended from trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.